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Background/aim: Platelet-rich plasma (PRP) application has gained widespread interest for musculoskeletal injuries. Nonsteroidal
antiinflammatory drugs are frequently used in sports medicine before and/or after PRP application. Our study seeks to determine
whether serum levels of platelet-derived growth factor-AB (PDGF-AB) and vascular endothelial growth factor (VEGF) levels of PRP
would be affected by nonsteroidal antiinflammatory drugs.
Materials and methods: Two different final concentrations of diclofenac (0.5 µg mL–1 and 2.5 µg mL–1), meloxicam (0.8 µg mL–1 and 2.0
µg mL–1), and acetylsalicylic acid (final concentration 450 µm) were obtained in separate tubes with PRPs prepared from 20 healthy male
volunteers. Medicine-free PRP was the control group. Growth factors were measured using ELISA.
Results: PDGF-AB and VEGF serum levels did not change with diclofenac, meloxicam, or acetylsalicylic acid addition. PDGF-AB and
VEGF serum levels correlated with each other.
Conclusion: Diclofenac, meloxicam, and acetylsalicylic acid did not affect PDGF-AB and VEGF serum levels.
Key words: Platelet-rich plasma, PDGF-AB, VEGF, nonsteroidal antiinflammatory drugs

1. Introduction
Platelet-derived growth factor (PDGF), endothelial
growth factor (EGF), insulin-like growth factor (IGF-I),
transforming growth factor-β-1 (TGF-β-l), vascular
endothelial growth factor (VEGF), hepatocyte growth
factor (HGF), and basic fibroblast growth factor (bFGF)
(1,2) that contain platelet-rich plasma (PRP) are frequently
used to treat musculoskeletal injuries (3,4).
Like other injections, PRP applications could
be painful, and clinicians may prefer to apply local
anesthetics before or after injections for relieving pain (5).
There are conflicting results concerning the interaction of
local anesthetics and PRP (5,6). In addition, nonsteroidal
antiinflammatory drug (NSAID) usage is also not
uncommon in athletes with acute or chronic pain (7,8).
NSAIDs are known to inhibit platelet aggregation by
inhibiting cyclooxygenase (COX) enzymes (Figure 1);
however, to our best knowledge, there are no clear data
about whether NSAIDs affect platelet activity. Since PDGF
* Correspondence: burkay.utku@gmail.com
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and VEGF stimulate cell proliferation and angiogenesis
and contribute to tissue regeneration (9,10), the research
questions of this study were as follows: whether reversible
COX-1 and COX-2 inhibitors, as well as irreversible
acetylsalicylic acid (ASA), affect serum PDGF and VEGF
concentrations, and whether PDGF and VEGF levels of
PRP correlate with each other according to different doses
of the drugs used in the study.
2. Materials and methods
2.1. Design
A cross-sectional in vitro controlled experiment was
designed. Independent variables were groups (n = 6)
(Table), and dependent variables were PDGF-AB and
VEGF levels of PRP measured with ELISA.
2.2. Participants
Twenty healthy males voluntarily participated. The
average age of participants was 24.0 ± 3.2 years (range:

UTKU et al. / Turk J Med Sci

Figure 1. Mechanism of the effects of diclofenac, meloxicam, and acetylsalicylic acid on platelet aggregation (ASA:
acetylsalicylic acid, COX-1: cyclooxygenase-1, COX-2: cyclooxygenase-2, PGH2: prostaglandin H2, TxA2: thromboxane A2,
PGD2: prostaglandin D2, PGE2: prostaglandin E2, PGF2α: prostaglandin F2α, PGI2: prostaglandin I2).

Table. Preparation of samples for each group. The final volume was 550 µL for each suspension.
Groups

PRP (µL)

Medicine (µL)

Saline (µL)

Final volume (µL)

Control

500

---

50.0

550

Diclofenac 0.5 µg/mL

500

5.5

44.5

550

Diclofenac 2.5 µg/mL

500

27.5

22.5

550

Meloxicam 0.8 µg/mL

500

11.0

39.0

550

Meloxicam 2.0 µg/mL

500

27.5

22.5

550

Acetylsalicylic acid (450 µm)

500

50.0

---

550
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18–35). Exclusion criteria included smoking, medication
for thrombocyte disorders, and alcohol consumption. The
institutional review board of the Hacettepe University Ethics
Committee approved the study (08.01.2014/16969557-15).
2.3. Platelet-rich plasma preparation
We briefly collected 20 mL samples of venous blood using
21 gauge butterfly needles (Dahlhausen Scalp Vein Set CE,
Cologne, Germany) into polypropylene tubes containing
3.2% buffered citrate (BD Vacutainer Systems, Plymouth,
UK) from the antecubital vein of each participant. This
was done by compressing the vein without applying a
vacuum following at least 3 h of fasting. Blood samples
were centrifuged at 580 × g for 8 min (Heraeus Labofuge
400R, Thermo Scientific, Waltham, MA, USA), and 4 mL
of PRP was obtained according to the Anitua technique
(11). Platelet and leukocyte counts of peripheral blood
and PRP were analyzed with a Beckman Coulter LH 780
device (Galway, Ireland). Platelet counts of PRP samples
were in the range of 244–692 × 106 mL–1 (mean: 456.1 ±
10.6 × 106 mL–1). Blood or PRP specimens of 250 µL taken
in polypropylene tubes were loaded into the device for
cellular count. Pearson’s correlation coefficient for platelet
counts of PRP and whole blood samples was rP = 0.91.
These data indicate that PRP preparations were successful
(11).
2.4. NSAIDs and supernatant collection
Reversible COX-1 and COX-2 inhibitor diclofenac,
reversible COX-2 inhibitor meloxicam, and irreversible
COX-1 inhibitor ASA were added to the test tubes
containing PRP.
Each PRP sample was divided into 6 tubes. We
added two different dosages of diclofenac (Diclomec,
Abdi İbrahim Pharmaceuticals, İstanbul, Turkey) and
meloxicam (Melox, Nobel İlaç, Düzce, Turkey) into tubes
to obtain 0.5 µg mL–1 and 2.5 µg mL–1 final concentrations
of diclofenac and meloxicam (12–14) in order to evaluate
the dose response. The same volumes of ASA (a final
concentration of 450 µm) and saline were added to other
PRP samples to have ASA and medicine-free groups as the
control (14–16). All test tubes were incubated for 20 min
at room temperature. PRP clots were formed by adding
27.5 µL of 10% calcium chloride to 0.55 mL of PRP. Clots
were allowed to retract for 20 to 30 min and were then
centrifuged at 1000 × g for 10 min (Hettich Mikro 200R
Centrifuges, Tuttlingen, Germany). Supernatants were
stored at –20 °C for subsequent ELISA analysis.
2.5. Growth factor concentration measurements
PDGF-AB and VEGF concentrations were measured using
a Quantikine Colorimetric Sandwich ELISA kit (R&D
Systems Inc., Minneapolis, MN, USA). All samples were
assayed in duplicate (SpectraMax Plus 384 Microplate
Reader, Sunnyvale, CA, USA) (3).
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2.6. Statistical analysis
Results were expressed as averages with standard
deviations. A Shapiro–Wilk test was used to check the
homogeneity of groups. A Friedman test was used to assess
the effect of medicines on VEGF levels, and a one-way
analysis of variance was used to compare the distribution
of PDGF-AB results. Statistical differences between groups
were accepted for P < 0.05 (StatGraphics Plus, Manugistics
Group, Rockland, MD, USA).
3. Results
After exposure to PRPs with each dose of the medicines,
the measured growth factor levels were similar among
groups (P > 0.05) (Figures 2 and 3). PDGF-AB and VEGF
serum levels correlated significantly (P < 0.05) with each
other when all PDGF-AB and VEGF data from whole
samples were pooled (Figure 4).
4. Discussion
There is no clear evidence whether NSAIDs affect platelet
activity in PRP injections. The research question of
this study was whether reversible and irreversible COX
inhibitors would decrease PDGF and VEGF serum levels
after PRP solutions were exposed to medicines.
Our results showed that adding diclofenac or
meloxicam in vitro with the dosages used in this study did
not change PDGF-AB and VEGF serum levels in the PRP
solution. Although ASA is known to irreversibly inhibit
platelet aggregation, adding ASA to the PRP solution also
did not change the amount of growth factors.
Increased cellular proliferation and vascularity are
the most important properties that PRP promotes in the
healing of musculoskeletal tissues, positively contributing
to the overall repair process. PDGF-AB plays a major role
in the chemotactic activity of PRP, along with other PDGF
ligands (17). It is also a potent mitogen for connective
tissue cells and enhances fibroblast proliferation. VEGF
is a powerful stimulator of angiogenesis, building new
vasculature to bring additional extrinsic cells, nutrients,
and growth factors to injured areas (18,19). Therefore, we
specifically analyzed these two growth factors (PDGF-AB
and VEGF).
Previous studies have assessed the antiaggregant effects
of diclofenac, meloxicam, and ASA in vitro. Yokoyama
et al. noted a 20% inhibition of platelet aggregation by
adding diclofenac and meloxicam. In the same study, the
inhibition rate of platelet aggregation was 60% to 80% with
ASA (16). In another study, a different dosage of diclofenac
(0.1–0.8 µg mL–1) and ASA (100 µm) were tested (14).
Diclofenac resulted in a dose-dependent increase in the
inhibition of platelet aggregation, and the inhibition rate
was much higher for ASA. We expected that NSAIDs and
ASA would suppress platelet secretion and growth factor
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Figure 2. Effects of diclofenac, meloxicam, and acetylsalicylic acid on PDGF-AB levels for all
groups (n = 20). The error bar represents the 95% confidence interval for PDGF-AB. There were
no significant differences among groups (P > 0.05).

Figure 3. Effects of diclofenac, meloxicam, and acetylsalicylic acid on VEGF levels for all groups (n =
20). The box plot represents the median line across the box and 25th and 75th percentiles. There were no
significant differences among groups (P > 0.05).
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Figure 4. PDGF-AB and VEGF levels of whole PRP samples are correlated (P = 0.0001, r = 0.4).

levels; however, such a result was not obtained. Adding
calcium to a PRP solution initiates the coagulation cascade
and, as a result, thrombin is formed (3). Thrombin binds to
protease-activated receptors (PAR-1) and initiates platelet
activation through the phospholipase C pathway. When
activated, platelets secrete their granule contents and
release growth factors (20,21). Findings in this study could
be explained by the highly stimulating effect of thrombin
on platelet secretion, which may hinder the antiaggregant
effects of NSAIDs and ASA.
Recently, two studies conducted by Anitua et al.
evaluated the serum growth factor levels (including
PDGF-AB and VEGF) and the proliferation capabilities
of PRPs in cell cultures obtained from chronic ASA users
(22,23). Similar to our findings, there were no significant
differences for the amounts of growth factors and
proliferation rates compared with the control groups.
Our study has shown that the growth factor levels of the
samples were not correlated with the number of platelets.
These findings support the result of Weibrich et al., who
evaluated 115 PRP samples and could not find any relation
between the platelet counts and the levels of growth factor
(24). These data support the notion that platelet counts in
a PRP solution may not be the only method to estimate
platelet secretion quality.
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PDGF-AB and VEGF are found in alpha granules and
secreted with the other growth factors described above.
Weibrich et al. (24) showed that there is a correlation
between PDGF-AB and TGF-β1 (rS = 0.78). Therefore, they
concluded that PDGF-AB serum levels could be used in
estimating TGF-β1 serum levels. To support that notion,
we found a significant correlation (P = 0.0001, r = 0.4)
between the serum levels of PDGF-AB and VEGF when all
6 groups were included in tests measuring the relationship
of these growth factors.
The study has some limitations. First, these medications
were tested only in vitro. Thus, we do not know if diclofenac,
meloxicam, or ASA would have any effect on the levels
of growth factors in vivo. Second, we only evaluated the
levels of PDGF-AB and VEGF. Therefore, we do not know
if other growth factors stored in platelets could be affected.
In order to eliminate the amount of growth factors coming
from leukocytes, we used a leukocyte-reduced PRP
preparation technique defined by Anitua for minimizing
the leukocyte effect (3,25). The number of leukocytes in
our PRP solutions was higher (1620 ± 771.57 µL–1) than
what Anitua reported before (3). Nonetheless, the previous
literature has shown that leukocytes have a poor growth
factor content (26). Therefore, we do not think that the
number of leukocytes in our study affected our results.

UTKU et al. / Turk J Med Sci
According to our study, diclofenac, meloxicam,
and ASA did not affect PDGF-AB and VEGF levels of
PRP in vitro. However, we cannot extrapolate from the
information gained here for clinical practice. Studies that
obtain PRPs from donors who are prescribed NSAIDs
need to examine their effects on PRP secretion in vivo.
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